Italy and the UAE are expecting specific benefits from the concluded partnerships, which will undoubtedly contribute not only to strengthening the relations between these countries but also to global achievements.
Today's cooperation in the field of investments in the pharmaceutical sector between the Ministry of Investment of the UAE and the Ministry of Industry and Production of Italy supports the commitment of both countries to developing cooperation in the health, biotechnology, and pharmaceutical sectors. These strategic partnerships underscore the commitment of the UAE, MGX, and G42 to strengthening major international alliances and promoting innovations based on artificial intelligence, at the global level.
The UAE and Italy have long nurtured robust political cooperation and major economic partnerships. Consequently, these agreements establish a framework for investment cooperation, facilitating the development of innovations, knowledge transfer, and the integration of technology and artificial intelligence for advancing value creation in the fields of life sciences, minerals, and technology in both countries.
The Memorandum on cooperation with Italy reflects our determined steps toward strengthening the economy and affirming our collective efforts for advancing sustainable economic growth,” stated the Minister of Investments of the UAE, Mohammad Hassan Al Suwaidi.
The Minister of Industry and Production of Italy, Adolfo Urso, added: "The signing of three memoranda on cooperation represents a significant step in strengthening the robust and long-term partnership between Italy and the UAE." The cooperation will focus on research and the development of new medicinal products in the UAE and beyond, utilizing the existing infrastructure and devising new pathways in the market.
An essential component of the partnership is also the focus on research and the development of new treatment methods, skill development through specialized training, and establishing strategic alliances with leading institutions and pharmaceutical companies. Key directions for innovation include oncology, cardiac-vascular and metabolic disorders, immunology, and rare diseases, addressing critical unmet patient needs.
